Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
about
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentialsEvaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography.Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation.Recent advances in antimultiple myeloma drug development.HSVtk/GCV system on hepatoma carcinoma cells: Construction of the plasmid pcDNA3.1‑pAFP-TK and targeted killing effectTexture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.Preclinical Study of Locoregional Therapy of Hepatocellular Carcinoma by Bioelectric Ablation with Microsecond Pulsed Electric Fields (μsPEFs).Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinomaNew molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.Targeting the tumor stroma in hepatocellular carcinoma.Significant biomarkers for the management of hepatocellular carcinoma.Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib TreatmentBiomarkers and Personalized Sorafenib Therapy.Slight elevation of high-sensitivity C-reactive protein to predict recurrence and survival in patients with early stage hepatitis C-related hepatocellular carcinoma.The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy
P2860
Q26824909-A9B9C6F3-C78E-44C8-93DC-31E1EA3889D2Q30365378-13732211-720A-4B98-9F72-296FD14AD37DQ30402324-FC4DB1E2-A66B-44C6-8C0F-BEA2FAF5D305Q33416297-3E7748B5-260B-4BB3-A914-1E5F07D8191AQ33828277-0E7C2E6A-E832-42CF-A372-66B3A7F4C199Q33914180-52971909-BDEF-4CA6-8665-E48661C6B7DFQ35556997-A1292664-EEC7-4D3D-B807-EFF56AF720BCQ35793100-FD089B7C-43CA-4C0B-952F-661619332D2CQ35811557-CD0BAA4B-0E4E-4CC7-9B47-98F32F65754FQ35888783-9E41319C-919E-4955-B266-BD47EBCBAD4DQ37031730-25DC91A1-BEA5-408A-AAF3-2132430AD178Q38282800-FE63B277-DD7D-48AC-A72D-AD319029B406Q38366586-16BA9E06-0A38-45DE-BB25-29C1AD417AD1Q38412315-C9541FA6-8B5B-4803-ABD0-BAC5177F939FQ39030388-7B5D62F7-8F50-4E2A-8017-38EAC597CE0CQ41024086-352FFA22-C542-4699-9906-96E20A5D5E3EQ41544562-DD7CFE14-F321-4D35-BA47-53853A74184CQ41879721-1D01B127-6E85-47C4-8EE8-425B3DB196B1Q42203320-26C02E00-E87A-4D03-83C4-165CC7D5DC3DQ44479261-85FB308D-C558-4D6B-BB47-72589F284439Q46124376-6126B2FF-FC58-4DF2-BD3C-50F8BBF8ACEEQ48188138-9C2EBA3B-71C7-4C3B-94CF-4E702BD8E478Q48368428-467276DF-21E9-4578-A425-C94BF66CEDF3Q57067866-C4F16167-D21A-4974-8254-A88BA94D8BD0Q57491231-F12F4FA1-F148-4DDE-9A8E-58E7EDC68743
P2860
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@ast
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@en
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@nl
type
label
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@ast
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@en
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@nl
prefLabel
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@ast
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@en
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Changes in plasma vascular end ...... nced hepatocellular carcinoma.
@en
P2093
Hiroyuki Nakanishi
Jun Itakura
Kaoru Tsuchiya
Masaru Muraoka
Masayuki Kurosaki
Namiki Izumi
Nobuharu Tamaki
Nobuyuki Enomoto
Shoko Suzuki
P2860
P304
P356
10.1002/CNCR.28384
P407
P577
2013-10-07T00:00:00Z